| Gretchen G Belzer-curl, MD | |
|
910 18th St Nw, Mandan, ND 58554-1612 | |
| (701) 667-5100 | |
| (701) 667-5095 |
| Full Name | Gretchen G Belzer-curl |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 38 Years |
| Location | 910 18th St Nw, Mandan, North Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699878405 | NPI | - | NPPES |
| 10356 | Medicaid | ND |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 7728 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Home Care | Mandan, ND | Home health agency |
| Sanford Medical Center Bismarck | Bismarck, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Bismarck | 9739098575 | 448 |
News Archive
The Legatum Foundation, the development arm of the Legatum Group, today announced a donation of $150,000 to the Ebola Crisis Fund, a fund established to help prevent the spread of the deadly Ebola virus in West Africa.
Researchers from Israel have investigated the possibility that vaccine-induced immunity reduces over time and potential causes and risk factors.
Both obesity and being underweight are associated with an increased risk for migraine, according to a meta-analysis published in the April 12, 2017, online issue of Neurology, the medical journal of the American Academy of Neurology.
Allos Therapeutics, Inc. today reported a new analysis of data from the Company's pivotal PROPEL trial of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated.
› Verified 8 days ago
| Entity Name | Sanford Bismarck |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811941172 PECOS PAC ID: 9739098575 Enrollment ID: O20031105000403 |
News Archive
The Legatum Foundation, the development arm of the Legatum Group, today announced a donation of $150,000 to the Ebola Crisis Fund, a fund established to help prevent the spread of the deadly Ebola virus in West Africa.
Researchers from Israel have investigated the possibility that vaccine-induced immunity reduces over time and potential causes and risk factors.
Both obesity and being underweight are associated with an increased risk for migraine, according to a meta-analysis published in the April 12, 2017, online issue of Neurology, the medical journal of the American Academy of Neurology.
Allos Therapeutics, Inc. today reported a new analysis of data from the Company's pivotal PROPEL trial of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gretchen G Belzer-curl, MD Po Box 5501, Bismarck, ND 58506-5501 Ph: (701) 323-6000 | Gretchen G Belzer-curl, MD 910 18th St Nw, Mandan, ND 58554-1612 Ph: (701) 667-5100 |
News Archive
The Legatum Foundation, the development arm of the Legatum Group, today announced a donation of $150,000 to the Ebola Crisis Fund, a fund established to help prevent the spread of the deadly Ebola virus in West Africa.
Researchers from Israel have investigated the possibility that vaccine-induced immunity reduces over time and potential causes and risk factors.
Both obesity and being underweight are associated with an increased risk for migraine, according to a meta-analysis published in the April 12, 2017, online issue of Neurology, the medical journal of the American Academy of Neurology.
Allos Therapeutics, Inc. today reported a new analysis of data from the Company's pivotal PROPEL trial of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated.
› Verified 8 days ago
Meghan Hendrickson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 102 Mandan Ave, Mandan, ND 58554 Phone: 701-323-6000 | |
Boyd F Addy, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2008 Twin City Dr, Mandan, ND 58554 Phone: 701-667-1000 Fax: 701-667-0707 | |
Dale A Klein, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 910 18th St Nw, Mandan, ND 58554 Phone: 701-667-5100 Fax: 701-323-5709 | |
Laura Archuleta, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2500 Sunset Drive Nw, Mandan, ND 58554 Phone: 701-667-4600 Fax: 701-530-3780 | |
Andrew Dockter, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 910 18th St Nw, Mandan, ND 58554 Phone: 701-667-5100 | |
Sadaf Yousuf, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 910 18th St Nw, Mandan, ND 58554 Phone: 701-667-5100 Fax: 701-667-5095 |